trending Market Intelligence /marketintelligence/en/news-insights/trending/0zjOeOSLmLlricnqJU7FHg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA approves Dexcom's glucose monitoring system

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA approves Dexcom's glucose monitoring system

The U.S. FDA approved DexCom Inc.'s G5 Mobile CGM system, a continuous glucose monitoring system, with a non-adjunctive designation.

In July, an FDA selected panel of experts deemed the system safe and effective, with its benefits outweighing the risks with the proposed indications for use. The FDA has followed the expert recommendation and made the system the first and only continuous glucose monitoring system in the U.S. to have a non-adjunctive designation.

The new non-adjunctive indication expands the use of the system as a replacement to finger stick glucose testing for diabetes treatment decisions. With the new label indication, the system only requires two finger pricks per day for calibration.